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The observation that obesity protects from osteoporosis suggested that energy metabolism and bone mass could be
regulated by the same hormones. Testing this hypothesis revealed that leptin regulates bone mass through a hypothalamic
relay and using two neural mediators, the sympathetic tone and CART, both acting on one cell type the osteoblast. This
review summarizes the genetic and molecular bases of this regulation and discusses its potential clinical implications.Although it is mainly known for, and tightly associated with, the
control of appetite, the adipocyte-derived hormone leptin is
more than an antiobesity molecule. Indeed, leptin is also amajor
regulator of reproduction and bone mass. This article will review
the genetic andmolecular evidence establishing that leptin con-
trols, through a regulatory loop including hypothalamic neurons
and two neural outputs, the proliferation and function of the
osteoblast and thereby bone mass. This body of work provides
the first evidence of a convergence between bone and energy
metabolisms.
Skeleton is a late acquisition during development; this ex-
plains why in most cases a very high degree of conservation ex-
ists between mice and humans in the function of genes involved
in skeletal biology. Indeed, whether those are regulatory mole-
cules such as transcription factors, kinases, cell membrane
receptors, secreted molecules, or structural proteins, inactiva-
tion of genes encoding these molecules results in essentially
identical phenotypes in both species (Karsenty and Wagner,
2002). This high degree of conservation between mice and hu-
man explains why mouse genetics has become so central to
our understanding of human skeletal biology and in uncovering
novel modes of regulation of bone mass.
The biological relevance of bone remodeling
Bone is constantly turned over through bone remodeling (Rodan
and Martin, 2000). This is a biphasic process occurring through-
out the skeleton over a period of approximately 3 months in ro-
dents. It includes destruction (resorption) of pre-existing bone, a
function exerted by a specialized bone-specific cell, the osteo-
clast, followed by de novo bone formation, a function of another
bone-specific cell, the osteoblast. Normally, resorption and for-
mation of bone occur not only sequentially but in a balanced
manner in order to maintain bone mass nearly constant during
most part of adulthood. This qualifies bone remodeling as a
true homeostatic function, a feature that, as explained below,
has important molecular implications.
What is the biological importance of bone remodeling? Now-
adays themaintenance of a constant bonemass is the aspect of
bone remodeling we are the most familiar with because osteo-
porosis, the most frequent bone disorder, is a bone remodeling
disease (Cooper and Melton, 1996). Clearly, the rising incidence
of this degenerative disease suffices to justify the research effort
in uncovering molecular bases of bone remodeling. Osteoporo-CELL METABOLISM 4, 341–348, NOVEMBER 2006 ª2006 ELSEVIER INCsis is caused by a relative increase of bone resorption over bone
formation (Raisz, 2005), an event most often triggered by go-
nadal failure (Riggs et al., 1998; Riggs and Melton, 1986).
Thus, it is a disease of people 50 years and older, and a disease
that became a public health concern during the 20th century,
when people began to outlive their own skeleton. The relatively
recent appearance of osteoporosismakes it an unlikely justifica-
tion for the conservation of bone remodeling during evolution.
In contrast, another aspect of bone remodeling has been of
critical importance for the survival of vertebrates throughout
evolution. Specifically, it is the ability of bones, through constant
cycles of destruction and formation, to repair micro- andmacro-
damages without surgical intervention and thereby to preserve
mobility. This aspect of bone remodeling is a survival function
for vertebrates, not only in the dark ages of evolution, but also
until few centuries ago.
Experimentally, bone remodeling can be studied directly us-
ing bone histology or indirectly by using bone mineral density
and measure of relevant biological markers in serum and urine.
In humans, for obvious ethical reasons, the study of bone re-
modeling relies only on indirect assays. In contrast, using the
mouse as an animal model presents the advantage that bone re-
modeling can be studied histologically. One can measure not
only bone mass but also the number and activity of osteoblasts
and of osteoclasts in vivo through histomorphometry, a tech-
nique providing amore dynamic view of bone remodeling. In ad-
dition, cell-based assays using cells derived from genetically
modified animals can be performed. This set of methodologies
has become over the years the gold standard to study bone
physiology.
A common endocrine control of body weight,
reproduction, and bone mass
Although remarkable progress has beenmade, the consensus in
the field is that we still do not know all the genetic andmolecular
mechanisms influencing bone remodeling. Uncovering novel
regulators of this process requires looking from both a concep-
tual and experimental point of view. Conceptually, because re-
sorption and formation of bone belong to the same physiological
function, this implies that the same classes of molecules should
regulate both of them. In agreement with this assumption, tran-
scription factors and cytokines of various sorts affect osteoclast
as well as osteoblast differentiation and function (Olsen et al.,. DOI 10.1016/j.cmet.2006.10.008 341
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remodeling is thehormonal regulation of bone resorption exerted
by, among others, sex steroids and the parathyroid hormone
(Potts and Juppner, 1998; Riggs et al., 1998).Yet surprisingly,
until recently the existence of an hormonal regulation of bone
formation had not been established. Such a discrepancy in the
regulation of two aspects of the same physiological function
appeared unlikely.
An experimental argument further supported the hypothesis
that bone formationmust be regulated by hormones. In amouse
model of inducible osteoblast ablation relying on cell-specific
expression of the Thymidine-kinase gene, gancyclovir treatment
resulted in the death of all osteoblasts and therefore in virtually
empty bones (Corral et al., 1998). The most informative aspect
of this experiment happened when the gancyclovir treatment
ceased. Remarkably, in a short period of time according to
bone remodeling standard (one month), the bone mass of these
transgenic mice returned to normal with a surprising precision.
The rapidity of this recovery indicated that osteoblasts could
sense when bones were empty and that they had to work at
full capacity to replenish them. The precision of this recovery im-
plied that osteoblasts could sense when bone mass had been
restored and that they could decrease their output. Such an
ability of osteoblasts, regardless of their location in the body,
to modulate their function depending on what bone mass is
could only be explained if hormonal and/or neural outputs
were regulating their function.
How could one identify hormone(s) regulating bone formation
without relying on a large genetic screen? As it is most often the
case in physiology, an answer to this question came from the
clinical literature. Two major clinical features of osteoporosis
are that: (1) osteoporosis invariably follows gonadal failure,
and (2) obesity protects from it. Taken together, these two
observations suggest the existence of a common regulation of
body weight (or appetite), reproduction, and bone mass. Al-
though this hypothesis sounds nonspecific, it is in fact rather
restrictive. Indeed, since appetite and reproduction are by and
large governed by the hypothalamus, this hypothesis implies
that the control of bone remodeling may also, in part, originate
from the hypothalamus. Although novel, this concept should
not be surprising, since most homeostatic functions are sub-
jected to hypothalamic regulation, and bone remodeling is a
prototypical homeostatic function.
Regulation of bone formation by leptin
Determining whether a common endocrine control of appetite,
reproduction, and bone mass exists required studying the influ-
ence of hormone(s) known to regulate appetite and reproduction
on bone remodeling. As it turned out, only one hormone signif-
icantly influences these two functions: leptin (Ahima, 2004; Spie-
gelman and Flier, 2001). Leptin inhibits appetite and favors
reproductive function; consequently, mice lacking either leptin
(ob/ob) or its receptor (db/db) are obese and sterile. From
a physiological and molecular point of view, leptin is a privileged
hormone to study for two reasons. First, there is only one ligand
and one receptor, making interpretation of any experiment sim-
pler (Tartaglia et al., 1995; Zhang et al., 1994). Second, during
the 40 years or so that passed between the identification of
the (ob/ob) and (db/db) mouse strains and the cloning of leptin
and its receptor, an impressive amount of information has
been gathered about the various phenotypic abnormalities342present in these mutant mice. This knowledge proved to be
invaluable in the study of leptin regulation of bone mass.
The sterility (or hypogonadism) of ob/ob and db/db mice
should increase their bone resorption. Indeed, osteoclast num-
bers and bone resorption parameters are increased in leptin
signaling-deficient (ob/ob and db/db) mice (Ducy et al., 2000).
Despite this, leptin signaling-deficient mice display a higher
bone mass than wild-type (WT) mice. This high bone mass,
affecting all bones in the body, is due to a massive increase in
bone formation parameters (Ducy et al., 2000). To date, leptin
signaling-deficient mice are still the only animal models in which
hypogonadism and high bone mass coexist. High bone mass
was also observed in a patient harboring an inactivating muta-
tion of the leptin gene (Elefteriou et al., 2005). Although this find-
ing was based on noninvasive approaches, it is profoundly
important since it represents the best available evidence that
the absence of leptin affects the function of osteoblasts in the
same manner in human and mice.
The high bone mass of ob/ob or db/db mice cannot be ex-
plained by their obesity since mice lacking adipocytes (‘‘fat-
free’’ mice) display the same phenotype (Ducy et al., 2000).
Moreover, a leptin transgene can correct the high bone mass
of fat-free mice, indicating that leptin is the adipocyte-derived
gene product responsible for their bone phenotype (Elefteriou
et al., 2004). Similarly, lipodystrophic patients present objective
evidence (advanced bone age) of an increase in the function of
osteoblasts, further indicating that this regulatory pathway is
conserved between mouse and human (Elefteriou et al., 2004).
It is worthwhile to note that glucocorticoid serum levels are
elevated in ob/obmice but not in lipodystrophic mice. Likewise,
glucocorticoid serum levels are normal in lipodystrophic leptin-
deficient patients. Yet, they all display an increase in bone
formation activity, demonstrating that the bone phenotype of
leptin signaling-deficient mice and humans is not linked to their
level of circulating glucocorticoids.
In full agreement with the restriction implied by the initial hy-
pothesis, intracerebroventricular (ICV) infusion of leptin in lep-
tin-deficient mice, at a rate that does not result in any detectable
leak of leptin in the general circulation, completely corrects their
high bonemass (Ducy et al., 2000). This experiment, in a ‘‘leptin-
less’’ animal, is strong experimental evidence that leptin uses a
central (presumably hypothalamic) relay to control bone mass,
as it does to mediate its other functions (Ahima et al., 2000;
Ahima, 2004). In addition, the complete rescue of the bone phe-
notype following leptin ICV infusion argues against any other
mode of action of leptin; if this were so, the rescue would only
have been partial. This is an important point, as addition of
supraphysiological amounts of leptin to WT animals do have
consequences not observed in the privileged context of loss-
of-function models (Cornish et al., 2002; Martin et al., 2005).
Several experimental arguments also indicate that leptin does
not act directly on osteoblasts. First, Stat3 phosphorylation can-
not be detected following treatment of primary osteoblast cul-
tures with physiological doses of leptin; an effect of leptin was
observed only when supraphysiological doses of the hormone
and osteoblastic cells differentiated in vitro were used (Ducy
et al., 2000; Thomas et al., 1999). Likewise, studies of peripheral
leptin injection in mice employed very high doses, which are
likely to induce leptin resistance and therefore bone loss (Cor-
nish et al., 2002; Martin et al., 2005). Second, if leptin action
were local, the high bone mass observed in db/db mice (whichCELL METABOLISM : NOVEMBER 2006
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defect. Yet, cultured osteoblasts from db/db mice did not pro-
duce any more extracellular matrix than WT osteoblasts (Ducy
et al., 2000). Third, transgenic mice expressing leptin in osteo-
blasts have no overt bone abnormalities (Takeda et al., 2002).
Thus, at the present time, there is no convincing evidence of
a direct action of leptin on osteoblasts in vivo.
Anatomical and molecular bases of leptin’s control
of bone formation
The identification of leptin-sensitive neurons controlling bone
formation has relied on chemical lesioning in WT and leptin
signaling–deficient mice, and on the use of other genetically
modified mouse models (Takeda et al., 2002). Monosodium glu-
tamate (MSG) treatment of WTmice lesions neurons of the arcu-
ate nuclei, resulting in increased appetite and obesity, but with
no effect on bone formation parameters. Likewise, mice lacking
themelanocortin 4 receptor (Mc4R), a receptor expressed on ar-
cuate neurons and involved in leptin’s control of appetite, have,
throughout their life, normal bone formation parameters (Huszar
et al., 1997; Vaisse et al., 1998). In contrast, lesioning neurons of
the ventromedial hypothalamic (VMH) nuclei using gold thioglu-
cose (GTG) induces an increase in bonemass due to an increase
in bone formation parameters similar to the increase observed
in ob/ob mice (Takeda et al., 2002). These experiments estab-
lished that hypothalamic neural networks regulating bone for-
mation exist. Yet, since they were performed in WT mice, they
did not prove that VMH-sensitive neurons regulate bone forma-
tion in a leptin-dependent manner. The proof came when ob/ob
mice with destroyed arcuate or VMH neurons received leptin
ICV infusion (Takeda et al., 2002). In the ob/ob mice whose
VMH neurons had been lesioned, leptin ICV infusion decreased
body weight but did not affect bone formation parameters or
bone mass. Conversely, leptin failed to decrease body weight
but decreased bone mass and bone formation in ob/ob mice
whose arcuate neurons had been lesioned. Thus, VMH neurons,
or more precisely GTG-sensitive neurons, regulate bone forma-
tion under the control of leptin. Recent efforts to determine
whether Sf1-expressing neurons located within the VMH nuclei
regulate bone mass were inconclusive, probably because no
histological analysis was performed (Dhillon et al., 2006).
What is the mediator of leptin’s regulation of bone formation?
An answer could be inferred from classical physiological studies
performed in ob/obmice, as well as from clinical observations. It
has long been known that ob/obmice have low sympathetic ac-
tivity (Bray and York, 1998). This observation naturally led to the
assumption that the sympathetic nervous system must mediate
leptin regulation of body weight and/or reproduction. This sup-
position was challenged however by the fact that Dbh-deficient
mice, unable to produce epinephrine and norepinephrine, were
neither obese nor sterile (Thomas and Palmiter, 1997). Two ex-
planations could account for the discrepancy between the ap-
petite and fertility phenotypes of the ob/ob and Dbh-deficient
mice. First, in the absence of sympathetic signalling, another
pathway might mediate leptin regulation of appetite and repro-
duction; although conceivable, this is a rather difficult hypothe-
sis to test. A second, simpler explanation could be that the low
sympathetic tone observed in ob/ob mice is not responsible for
their obesity or their sterility, but rather relates to another pheno-
type caused by leptin deficiency, for instance high bone mass.
In other words, the sympathetic tone would not be primarilyCELL METABOLISM : NOVEMBER 2006a mediator of leptin regulation of appetite or reproduction. The
testability of this hypothesis made it attractive. A clinical obser-
vation gave it further credence: patients with reflex sympathetic
dystrophy, a disease characterized by localized high sympa-
thetic activity, develop a severe and localized osteoporosis
that can be improved by b blockers (Kurvers, 1998). That oste-
oporosis develops in these patients without impairment of en-
ergy expenditure provides in vivo evidence that the sympathetic
tone regulates bone mass independently of any influence it may
have on energy expenditure.
If indeed sympathetic tone mediates leptin regulation of bone
mass selectively, then a series of inferences could be made and
tested: (1) Dbh-deficient mice should have high bone mass, (2)
this high bone mass should be resistant to leptin ICV infusion,
and (3) this infusion should decrease fat and body weight. All
these hypotheses turned out to be correct (Takeda et al.,
2002). More importantly, restoring sympathetic activity in
ob/ob mice had no measurable effect on food intake and body
weight but led to a 45%decrease in bonemass. Taken together,
these lines of evidence demonstrate that in animals fed a nor-
mal diet the sympathetic nervous system mediates only leptin’s
regulation of bone mass.
Molecular bases of leptin control of bone formation
Fortunately only one adrenergic receptor, the b2 adrenergic
receptor (Adrb2), is expressed in osteoblasts (Takeda et al.,
2002), and mice lacking this receptor had already been gener-
ated (Chruscinski et al., 1999). As implied by the data presented
above Adrb2-deficient mice are not obese, are fertile, and have
none of the metabolic abnormalities seen in ob/ob and db/db
mice (Chruscinski et al., 1999; Elefteriou et al., 2005). Yet, they
display an increase in bone formation and in bone mass that
cannot be rescued by leptin ICV infusion. This latter experiment
established genetically that the sympathetic nervous system, via
Adrb2, mediates leptin regulation of bone mass (Elefteriou et al.,
2005; Takeda et al., 2002). Because Adrb2-deficient mice have
no overt endocrine abnormalities, it also formally establishes
that the high bone mass observed in absence of leptin signaling
is not secondary to any metabolic perturbations. Subsequent
bone marrow transplantation experiments demonstrated that
the sympathetic regulation of bone formation directly occurs at
the level of the osteoblasts (Elefteriou et al., 2005).
How does sympathetic signaling in osteoblasts affect their
function so profoundly? The homeostatic nature of bone remod-
eling was a pivotal element in formulating a testable hypothesis.
Most homeostatic functions are regulated in a circadian manner
(Lowrey and Takahashi, 2004; Perreau-Lenz et al., 2004), raising
the hypothesis that bone remodeling is also subjected to circa-
dian regulation and therefore regulated by the molecular clock.
Consistent with this, the secretion of the two most abundant
proteins made by osteoblasts, Type I collagen and Osteocalcin,
cycles during a 24 hr period (Gundberg et al., 1985; Simmons
and Nichols, 1966).
Anatomically, the circadian clock includes a central compo-
nent located in the suprachiasmatic nucleus of the hypothala-
mus and subordinate components present in peripheral tissues
(Morse and Sassone-Corsi, 2002). Molecularly, both clock com-
ponents comprise key genes regulating each other’s expres-
sion. Schematically, ‘‘the engine’’ of the clock is composed of
Bmal1 and Clock, two bHLH-PAS transcription factors that het-
erodimerize to regulate the expression of other core circadian343
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genes, Rora, and Rev-erba. PER and CRY form a complex
that inhibits the expression and function of Bmal1 and Clock
(Reppert and Weaver, 2002; Schibler and Naef, 2005). Mutant
mice lacking molecular clock components have been gener-
ated, and most of them exhibit disruption of circadian rhythmic-
ity (Okamura et al., 1999; Zheng et al., 2001). Most of these
mutant mice, such as the Per1; Per2-deficient or Cry1; Cry2-
deficient mice, have a normal appetite and body weight, are fer-
tile, and display no overt endocrine or metabolic perturbations
when fed a normal diet. Because of this absence of metabolic
abnormalities, mice with a disrupted circadian rhythm are ideal
models to determine whether the molecular clock regulates
bone formation directly.
Multiple mutant mouse strains lacking one or several clock
genes were analyzed; they all displayed a similar increase in
bone formation parameters (Fu et al., 2005). For various reasons
Per-deficient mice were used as a model of choice for subse-
quent work. The normal serum levels of free leptin and normal
sympathetic activity of Per-deficient mice ruled out that the mo-
lecular clock acts upstream of leptin to regulate bone formation.
In contrast, leptin ICV infusion of Per-deficient mice increases
bone mass, while leptin decreases bone mass in WT mice.
This suggests that components of the molecular clock mediate,
in osteoblasts, the leptin-dependent sympathetic regulation of
bone formation. Accordingly, most components of the molecu-
lar clock are expressed in osteoblasts, where their expression
cycles during a 24 hr period and is regulated by the sympathetic
tone (Fu et al., 2005). Furthermore, osteoblast-specific deletion
of the Per genes results in high bone mass due to an increase
in bone formation. Altogether these observations support the
hypothesis that components of the molecular clock mediate,
in osteoblasts, the leptin-dependent sympathetic regulation of
bone formation.
Per-deficient and Adrb2-deficient osteoblasts progress faster
through the G1 phase of the cell cycle than WT osteoblasts (Fu
et al., 2005). Expression of all D-type Cyclin and of Cyclin E is
increased in Per-deficient as well as in Adrb2-deficient osteo-
blasts, and sympathetic tone inhibits G1 cyclin, D-type Cyclin
and Cyclin E expression in WT osteoblasts. While there is no
evidence that Bmal and Clock regulate Cyclin D1 expression di-
rectly, they inhibit the activity of thepromoter ofc-myc, an impor-
tant regulator of Cyclin D1 expression. This decrease in c-myc
expression probably results in decreased Cyclin D1 expression.
The similarity between Adrb2-deficient and Per-deficient mice
suffers one significant exception: ICV infusion of leptin increases
osteoblast numbers in Per-deficient, not in Adrb2-deficient
mice. This aspect of leptin regulation of bone formation could
not have been observed by the study of ob/ob and Adrb2-defi-
cient mice. Indeed, this discrepancy between Adrb2-deficient
and Per-deficient mice implies that sympathetic signaling exerts
two influences on osteoblast proliferation, one negative and
dominant through the molecular clock, and one positive, visible
only upon disruption of the molecular clock. Subsequent exper-
iments showed that c-fos (a critical regulator of bone remodeling
(Jochum et al., 2001)) and other members of the AP-1 family are
overexpressed in osteoblasts lacking either Per or Adrb2. This
in turn favors expression of c-myc and thereby osteoblast pro-
liferation via increased Cyclin D1 expression (Fu et al., 2005).
In agreement with this regulatory cascade, AP-1 gene expres-
sion in WT osteoblasts is regulated by both leptin and the344sympathetic tone. This regulatory loop is not apparent in ob/
obmice because themolecular clock inhibits AP-1 gene expres-
sion in these animals.
Together, genetic and molecular studies provide a detailed
picture of how leptin regulates bone formation (Figure 1). Follow-
ing binding to its receptor on VMH neurons leptin uses sympa-
thetic signaling as its only identifiable mediator to negatively
act on osteoblasts. In these cells sympathetic signaling exerts
two actions: one through AP-1 favors osteoblast proliferation,
and another one, through the molecular clock, inhibits osteo-
blast proliferation by affecting both D type cyclin and AP-1
gene expression (Figure 2).
Regulation of bone resorption by leptin
The work presented above was prompted by the assumption
that identical classes of molecules must regulate the two as-
pects of bone remodeling, formation, and resorption. Demon-
strating that bone formation is hormonally regulated verified
this hypothesis but also uncovered a neural regulation of bone
formation. The logic of the original hypothesis would then pre-
dict that bone resorption should be regulated by neural means.
The demonstration that this indeed was the case came again
from the analysis of the Adrb2-deficient mice (Elefteriou et al.,
2005). Quite surprisingly, these mutant mice not only present
an increase in bone formation, but also a decrease in bone re-
sorption parameters (Figure 3). This latter abnormality, which
contributes to the Adrb2-deficient mice high bone mass, cannot
be corrected by leptin ICV infusion indicating that leptin via the
sympathetic tone regulates bone resorption.
The differentiation of the osteoclast, the bone resorbing cell, is
determined by osteoblasts which produce the two main regula-
tors of osteoclast differentiation: M-CSF, a survival factor for
osteoclast progenitor cells, and RANKL, a true osteoclast differ-
entiation factor (Teitelbaum and Ross, 2003). Coculture of oste-
oblasts and osteoclast precursors revealed that sympathetic
signaling regulates osteoclast differentiation by regulating ex-
pression of Rankl in osteoblasts (Elefteriou et al., 2005). The bio-
logical importance of this regulation was demonstrated through
gonadectomy, a procedure that increases bone resorption and
decreasesbonemass. Followinggonadectomy, bone resorption
parameters and bone mass remained unaffected in Adrb2-defi-
cient mice, indicating that the integrity of the sympathetic ner-
vous system is required for the bone loss that follows gonadal
failure.
This experiment uncovered another aspect of the complex
regulation of bone mass by leptin. Indeed, from a bone biology
perspective gonadectomized Adrb2-deficient mice should be
a phenocopy of ob/obmice since both mousemodels are hypo-
gonadic and have a low sympathetic tone. Yet, they differ in a
major way: while gonadectomized Adrb2-deficient mice have
normal bone resorption activity, ob/ob mice have high bone
resorption activity (Elefteriou et al., 2005). The increase in
bone resorption observed in ob/ob mice therefore cannot be
due to their hypogonadism; otherwise, gonadectomized
Adrb2-deficient mice would also have an increase in bone re-
sorption. This difference could be explained by a speculative
ability of leptin to regulate the expression of gene(s) controlling
osteoclast differentiation.
The fact that all the molecules identified as mediating leptin
regulation of bone mass mediate only this function suggested
that this specificity might also apply to leptin-dependent controlCELL METABOLISM : NOVEMBER 2006
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regulation of bone mass
Leptin binds to its hypothalamic receptors and in-
duces two cascades to control bone mass. In the
arcuate nuclei, it increases Cart expression that in
turn regulates, via an unknown mechanism, RankL
expression by osteoblasts and thereby bone resorp-
tion. Leptin also binds to receptors on the GTG-
sensitive neurons of the VMH nuclei, inducing an
increase in sympathetic activity which signals to
osteoblasts via the b2 adrenergic receptors present
at their surface. Two distinct molecular cascades
downstream of this receptor are then activated.
One inhibits osteoblast proliferation via the molecu-
lar clock regulation of c-myc and Cyclin-D expres-
sion. The other, mediated by PKA phosphorylation
of ATF4, promotes Rankl expression and thereby
bone resorption.of osteoclast differentiation. One gene expressed in various
parts of the brain and whose expression is increased by leptin
and decreased in ob/ob mice, is Cart (cocaine amphetamine
regulated transcript) (Elias et al., 1998; Kristensen et al., 1998).
Cart-deficient mice have a normal appetite and are fertile, but
display an osteoporosis phenotype due to an isolated increase
in bone resorption parameters (Asnicar et al., 2001; Elefteriou
et al., 2005) (Figure 4). Two other lines of evidence, one coming
from mouse genetics the other from human genetics, under-
scored CART’s biological importance as a regulator of osteo-
clast differentiation. First, Mc4R-deficient mice, that show a 2-
fold increase in hypothalamic Cart expression, present a highCELL METABOLISM : NOVEMBER 2006bone mass with an isolated decrease in bone resorption param-
eters (Elefteriou et al., 2005), a phenotype corrected by simply
deleting Cart (Ahn et al., 2006). Remarkably, Cart deletion did
not improve the metabolic abnormalities observed in the
Mc4R2/2 mice, adding further credence to the notion that Cart
is only amediator of leptin regulation of bonemass. Second, pa-
tients deficient in MC4R have been reported to display an in-
crease in bone mineral density, an indirect measure of bone
mass (Farooqi et al., 2000). Biochemical analysis of the serum
of these patients showed that they have an increase in CART
levels and in biomarkers of bone resorption activity (Ahn et al.,
2006). Thus, both loss- and gain-of-function experimentsFigure 2. Schematic representation of the modifica-
tions caused by Per1/2 or Cry1/2 inactivation on the
leptin-dependent regulation of bone mass
Upon inactivation of the molecular clock, the leptin/
SNS arm regulating osteoblast proliferation via
c-myc and CyclinD is overactivated, leading to an
increase in bone formation and thus a high bone
mass phenotype.345
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tions caused by Adrb2 inactivation on the leptin-
dependent regulation of bone mass
Inactivation of b2 adrenergic signaling leads to high
bone mass. It increases bone formation by inhibiting
the negative regulation exerted by the molecular
clock on osteoblast proliferation. In addition, it de-
creases bone resorption by limiting the ATF4-medi-
ated regulation of Rankl expression.support the notion that CART is a regulator of bone resorption in
rodents and in humans. This latter point was further confirmed
by the finding that CART polymorphism affects bone mass
in post-menopausal women (Guerardel et al., 2006). These hu-
man genetic data all support the notion that the leptin-depen-
dent regulation of bone mass is conserved between mice and
humans.
In summary, as in the control of bone formation, leptin regu-
lates bone resorption through two antagonistic pathways (Fig-
ure 1). On the one hand, leptin favors resorption through the
sympathetic nervous system, while on the other hand, it inhibits
this function through CART (Figure 4). The absence of CART346probably explains the increased bone resorption observed in
the ob/ob mice (Elefteriou et al., 2005).
Summary and perspectives
This body of work illustrates the power of mouse genetics to
study biological functions in adult animals, to uncover unappre-
ciated regulatory loops and to provide the molecular bases of
these regulatory loops. As mentioned before, because leptin
and bony skeleton appear together during evolution the function
of several key components of this pathway such as leptin itself,
the sympathetic tone, or CART could be confirmed directly or
indirectly in humans. Despite the importance of this regulatoryFigure 4. Schematic representation of the modifi-
cations caused by Cart inactivation on the leptin-
dependent regulation of bone mass
Cart absence leads to a decrease in bone mass be-
cause of an isolated increase in osteoclast activity
following Rankl overexpression by osteoblasts.CELL METABOLISM : NOVEMBER 2006
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metabolic diseases from osteoporosis to renal osteodystrophy.
Rather, it provides one additional piece of knowledge that may
influence our understanding of osteoporosis pathophysiology.
The notion that an adipocyte-derived hormone regulates bone
mass through a hypothalamic relays and two neural outputs
raises a novel series of questions. First, how do osteoblasts,
the ultimate target cell of leptin regulation of bone mass, dictate
to adipocytes or neurons how much leptin, catecholamine, or
CART they should release? A second question, closer to leptin
regulation bone resorption, is to elucidate the molecular details
of CART signaling, to the level achieved for sympathetic regula-
tion of osteoblast functions. A third question, which has already
begun to be addressed, is whether other adipokines or neuro-
peptides regulate bone mass.
Finally, the regulation of bonemass by leptin has clinical impli-
cations. Indeed, the observation that gonadectomized Adrb2-
deficient mice fail to develop osteoporosis suggests that the
integrity of the sympathetic nervous system is necessary for
bone loss following menopause. The clinical significance of
this stems, in part, from the existing use of b blockers as generic
drugs with little toxicity. Several retrospective studies have
suggested that inhibition of sympathetic signaling may protect
osteoporotic women from bone fracture (Pasco et al., 2004; Re-
jnmark et al., 2006; Schlienger et al., 2004; Turker et al., 2006).
For now, only one prospective clinical trial of limited scope
has been reported, and its results look encouraging if not prom-
ising (Turker et al., 2006). Such an extension of this basic sci-
ence work, into the realm of clinical science, will take several
years to reach a firm conclusion.
References
Ahima, R.S. (2004). Body fat, leptin, and hypothalamic amenorrhea. N. Engl.
J. Med. 351, 959–962.
Ahima, R.S., Saper, C.B., Flier, J.S., and Elmquist, J.K. (2000). Leptin regula-
tion of neuroendocrine systems. Front. Neuroendocrinol. 21, 263–307.
Ahn, J.D., Dubern, B., Lubrano-Berthelier, C., Clement, K., and Karsenty, G.
(2006). Cart overexpression is the only identifiable cause of high bone mass
in Mc4R deficiency. Endocrinology, in press.
Asnicar, M.A., Smith, D.P., Yang, D.D., Heiman, M.L., Fox, N., Chen, Y.F.,
Hsiung, H.M., and Koster, A. (2001). Absence of cocaine- and amphet-
amine-regulated transcript results in obesity in mice fed a high caloric diet.
Endocrinology 142, 4394–4400.
Bray, G.A., and York, D.A. (1998). The MONA LISA hypothesis in the time of
leptin. Recent Prog. Horm. Res. 53, 95–117.
Chruscinski, A.J., Rohrer, D.K., Schauble, E., Desai, K.H., Bernstein, D., and
Kobilka, B.K. (1999). Targeted disruption of the beta2 adrenergic receptor
gene. J. Biol. Chem. 274, 16694–16700.
Cooper, C., and Melton, L.J.I. (1996). Magnitude and impact of osteoporosis
and fractures. In Osteoporosis, R. Marcus, D. Feldman, and J. Kelsey, eds.
(San Diego: Academic Press), pp. 419–434.
Cornish, J., Callon, K.E., Bava, U., Lin, C., Naot, D., Hill, B.L., Grey, A.B.,
Broom, N., Myers, D.E., Nicholson, G.C., and Reid, I.R. (2002). Leptin directly
regulates bone cell function in vitro and reduces bone fragility in vivo.
J. Endocrinol. 175, 405–415.
Corral, D.A., Amling, M., Priemel, M., Loyer, E., Fuchs, S., Ducy, P., Baron,
R., and Karsenty, G. (1998). Dissociation between bone resorption and
bone formation in osteopenic transgenic mice. Proc. Natl. Acad. Sci. USA
95, 13835–13840.CELL METABOLISM : NOVEMBER 2006Dhillon, H., Zigman, J.M., Ye, C., Lee, C.E., McGovern, R.A., Tang, V., Kenny,
C.D., Christiansen, L.M., White, R.D., Edelstein, E.A., et al. (2006). Leptin di-
rectly activates SF1 neurons in the VMH, and this action by leptin is required
for normal body-weight homeostasis. Neuron 49, 191–203.
Ducy, P., Amling, M., Takeda, S., Priemel, M., Schilling, A.F., Beil, F.T., Shen,
J., Vinson, C., Rueger, J.M., and Karsenty, G. (2000). Leptin inhibits bone for-
mation through a hypothalamic relay: a central control of bone mass. Cell
100, 197–207.
Elefteriou, F., Ahn, J.D., Takeda, S., Starbuck, M., Yang, X., Liu, X., Kondo,
H., Richards, W.G., Bannon, T.W., Noda, M., et al. (2005). Leptin regulation
of bone resorption by the sympathetic nervous system and CART. Nature
434, 514–520.
Elefteriou, F., Takeda, S., Ebihara, K., Magre, J., Patano, N., Kim, C.A.,
Ogawa, Y., Liu, X., Ware, S.M., Craigen, W.J., et al. (2004). Serum leptin level
is a regulator of bone mass. Proc. Natl. Acad. Sci. USA 101, 3258–3263.
Elias, C.F., Lee, C., Kelly, J., Aschkenasi, C., Ahima, R.S., Couceyro, P.R.,
Kuhar, M.J., Saper, C.B., and Elmquist, J.K. (1998). Leptin activates hypotha-
lamic CART neurons projecting to the spinal cord. Neuron 21, 1375–1385.
Farooqi, I.S., Yeo, G.S., Keogh, J.M., Aminian, S., Jebb, S.A., Butler, G.,
Cheetham, T., and O’Rahilly, S. (2000). Dominant and recessive inheritance
of morbid obesity associated with melanocortin 4 receptor deficiency.
J. Clin. Invest. 106, 271–279.
Fu, L., Patel, M.S., Bradley, A., Wagner, E.F., and Karsenty, G. (2005). The
molecular clock mediates leptin-regulated bone formation. Cell 122, 803–
815.
Guerardel, A., Tanko, L.B., Boutin, P., Christiansen, C., and Froguel, P.
(2006). Obesity susceptibility CART gene polymorphism contributes to
bone remodeling in postmenopausal women. Osteoporos. Int. 17, 156–157.
Gundberg, C.M., Markowitz, M.E., Mizruchi, M., and Rosen, J.F. (1985).
Osteocalcin in human serum: a circadian rhythm. J. Clin. Endocrinol. Metab.
60, 736–739.
Huszar, D., Lynch, C.A., Fairchild-Huntress, V., Dunmore, J.H., Fang, Q.,
Berkemeier, L.R., Gu, W., Kesterson, R.A., Boston, B.A., Cone, R.D., et al.
(1997). Targeted disruption of the melanocortin-4 receptor results in obesity
in mice. Cell 88, 131–141.
Jochum,W., Passegue, E., andWagner, E.F. (2001). AP-1 in mouse develop-
ment and tumorigenesis. Oncogene 20, 2401–2412.
Karsenty, G., and Wagner, E.F. (2002). Reaching a genetic and molecular
understanding of skeletal development. Dev. Cell 2, 389–406.
Kristensen, P., Judge, M.E., Thim, L., Ribel, U., Christjansen, K.N., Wulff,
B.S., Clausen, J.T., Jensen, P.B., Madsen, O.D., Vrang, N., et al. (1998).
Hypothalamic CART is a new anorectic peptide regulated by leptin. Nature
393, 72–76.
Kurvers, H.A. (1998). Reflex sympathetic dystrophy: facts and hypotheses.
Vasc. Med. 3, 207–214.
Lowrey, P.L., and Takahashi, J.S. (2004). Mammalian circadian biology: elu-
cidating genome-wide levels of temporal organization. Annu. Rev. Genomics
Hum. Genet. 5, 407–441.
Martin, A., de Vittoris, R., David, V., Moraes, R., Begeot, M., Lafage-Proust,
M.H., Alexandre, C., Vico, L., and Thomas, T. (2005). Leptin modulates both
resorption and formation while preventing disuse-induced bone loss in
tail-suspended female rats. Endocrinology 146, 3652–3659.
Morse, D., and Sassone-Corsi, P. (2002). Time after time: inputs to and out-
puts from the mammalian circadian oscillators. Trends Neurosci. 25, 632–
637.
Okamura, H., Miyake, S., Sumi, Y., Yamaguchi, S., Yasui, A., Muijtjens, M.,
Hoeijmakers, J.H., and van der Horst, G.T. (1999). Photic induction of
mPer1 and mPer2 in cry-deficient mice lacking a biological clock. Science
286, 2531–2534.
Olsen, B.J., Reginato, A.M., andWang, W. (2000). Bone Development. Annu.
Rev. Cell Dev. Biol. 16, 191–220.347
R E V I E WPasco, J.A., Henry, M.J., Sanders, K.M., Kotowicz, M.A., Seeman, E., and
Nicholson, G.C. (2004). Beta-adrenergic blockers reduce the risk of fracture
partly by increasing bone mineral density: Geelong Osteoporosis Study.
J. Bone Miner. Res. 19, 19–24.
Perreau-Lenz, S., Pevet, P., Buijs, R.M., and Kalsbeek, A. (2004). The biolog-
ical clock: the bodyguard of temporal homeostasis. Chronobiol. Int. 21, 1–25.
Potts, J.T., and Juppner, H. (1998). Parathyroid hormone and parathyroid
hormone-related peptide in calcium homeostasis, bone metabolism and
bone development: the proteins, their genes and receptors. In Metabolic
Bone Disease and Clinically Related Disorders, A. Press, ed. (San Diego:
Academic Press), pp. 52–94.
Raisz, L.G. (2005). Clinical practice. Screening for osteoporosis. N. Engl.
J. Med. 353, 164–171.
Rejnmark, L., Vestergaard, P., andMosekilde, L. (2006). Treatment with beta-
blockers, ACE inhibitors, and calcium-channel blockers is associated with
a reduced fracture risk: a nationwide case-control study. J. Hypertens. 24,
581–589.
Reppert, S.M., and Weaver, D.R. (2002). Coordination of circadian timing in
mammals. Nature 418, 935–941.
Riggs, B.L., Khosla, S., and Melton, L.J., 3rd. (1998). A unitary model for in-
volutional osteoporosis: estrogen deficiency causes both type I and type II
osteoporosis in postmenopausal women and contributes to bone loss in
aging men. J. Bone Miner. Res. 13, 763–773.
Riggs, B.L., and Melton, L.J., 3rd. (1986). Involutional osteoporosis. N. Engl.
J. Med. 314, 1676–1686.
Rodan, G.A., and Martin, T.J. (2000). Therapeutic approaches to bone dis-
eases. Science 289, 1508–1514.
Schibler, U., and Naef, F. (2005). Cellular oscillators: rhythmic gene expres-
sion and metabolism. Curr. Opin. Cell Biol. 17, 223–229.
Schlienger, R.G., Kraenzlin, M.E., Jick, S.S., and Meier, C.R. (2004). Use of
beta-blockers and risk of fractures. JAMA 292, 1326–1332.348Simmons, D.J., and Nichols, G., Jr. (1966). Diurnal periodicity in the meta-
bolic activity of bone tissue. Am. J. Physiol. 210, 411–418.
Spiegelman, B.M., and Flier, J.S. (2001). Obesity and the regulation of energy
balance. Cell 104, 531–543.
Takeda, S., Elefteriou, F., Levasseur, R., Liu, X., Zhao, L., Parker, K.L., Arm-
strong, D., Ducy, P., and Karsenty, G. (2002). Leptin regulates bone formation
via the sympathetic nervous system. Cell 111, 305–317.
Tartaglia, L.A., Dembski, M., Weng, X., Deng, N., Culpepper, J., Devos, R.,
Richards, G.J., Campfield, L.A., Clark, F.T., Deeds, J., et al. (1995). Identifi-
cation and expression cloning of a leptin receptor, OB-R. Cell 83, 1263–1271.
Teitelbaum, S.L., and Ross, F.P. (2003). Genetic regulation of osteoclast
development and function. Nat. Rev. Genet. 4, 638–649.
Thomas, S.A., and Palmiter, R.D. (1997). Impaired maternal behavior in mice
lacking norepinephrine and epinephrine. Cell 91, 583–592.
Thomas, T., Gori, F., Khosla, S., Jensen, M.D., Burguera, B., and Riggs, B.L.
(1999). Leptin acts on human marrow stromal cells to enhance differentiation
to osteoblasts and to inhibit differentiation to adipocytes. Endocrinology 140,
1630–1638.
Turker, S., Karatosun, V., and Gunal, I. (2006). Beta-blockers increase bone
mineral density. Clin. Orthop. Relat. Res. 443, 73–74.
Vaisse, C., Clement, K., Guy-Grand, B., and Froguel, P. (1998). A frameshift
mutation in human MC4R is associated with a dominant form of obesity.
Nat. Genet. 20, 113–114.
Zhang, Y., Proenca, R., Maffei, M., Barone, M., Leopold, L., and Friedman,
J.M. (1994). Positional cloning of the mouse obese gene and its human
homologue. Nature 372, 425–432.
Zheng, B., Albrecht, U., Kaasik, K., Sage,M., Lu,W., Vaishnav, S., Li, Q., Sun,
Z.S., Eichele, G., Bradley, A., and Lee, C.C. (2001). Nonredundant roles of
the mPer1 and mPer2 genes in the mammalian circadian clock. Cell 105,
683–694.CELL METABOLISM : NOVEMBER 2006
